Abstract

Allosteric modulators are highly desirable as drugs, particularly for G-protein-coupled receptor (GPCR) targets, because allosteric drugs can achieve selectivity between closely related receptors. The mechanisms by which allosteric modulators achieve selectivity remain elusive, however, particularly given recent structures that reveal similar allosteric binding sites across receptors. Here we show that positive allosteric modulators (PAMs) of the M1 muscarinic acetylcholine receptor (mAChR) achieve exquisite selectivity by occupying a dynamic pocket absent in existing crystal structures. This cryptic pocket forms far more frequently in molecular dynamics simulations of the M1 mAChR than in those of other mAChRs. These observations reconcile mutagenesis data that previously appeared contradictory. Further mutagenesis experiments validate our prediction that preventing cryptic pocket opening decreases the affinity of M1-selective PAMs. Our findings suggest opportunities for the design of subtype-specific drugs exploiting cryptic pockets that open in certain receptors but not in other receptors with nearly identical static structures.

Details

Title
Cryptic pocket formation underlies allosteric modulator selectivity at muscarinic GPCRs
Author
Hollingsworth, Scott A 1   VIAFID ORCID Logo  ; Kelly, Brendan 2   VIAFID ORCID Logo  ; Valant, Celine 3 ; Michaelis, Jordan Arthur 3 ; Mastromihalis, Olivia 3 ; Thompson, Geoff 3 ; Venkatakrishnan, A J 2 ; Hertig, Samuel 2 ; Scammells, Peter J 3 ; Sexton, Patrick M 3   VIAFID ORCID Logo  ; Felder, Christian C 4 ; Christopoulos, Arthur 3 ; Dror, Ron O 2   VIAFID ORCID Logo 

 Departments of Computer Science, Molecular and Cellular Physiology, and Structural Biology, and Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA, USA; Merck & Co., Boston, MA, USA 
 Departments of Computer Science, Molecular and Cellular Physiology, and Structural Biology, and Institute for Computational and Mathematical Engineering, Stanford University, Stanford, CA, USA 
 Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences and Department of Pharmacology, Monash University, Parkville, VIC, Australia 
 Eli Lilly and Co., Neuroscience, Lilly Corporate Center, Indianapolis, IN, USA; Karuna Pharmaceuticals, Inc., South San Francisco, CA, USA 
Pages
1-9
Publication year
2019
Publication date
Jul 2019
Publisher
Nature Publishing Group
e-ISSN
20411723
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2275920963
Copyright
© 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.